Prevention of mother-to-child transmission of hepatitis B virus in Burkina Faso: Screening, vaccination and evaluation of post-vaccination antibodies against hepatitis B surface antigen in newborns

  • Edwige T. Yelemkoure Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou; Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
  • Albert T. Yonli Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou; Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
  • Carla Montesano Department of Biology, Tor Vergata University of Rome, Italy.
  • Abdoul Karim Ouattara Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou; Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
  • Birama Diarra Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou; Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
  • Théodora M. Zohoncon Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou; Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
  • Christelle W.M. Nadembega Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou, Burkina Faso.
  • Paul Ouedraogo Saint Camille Hospital of Ouagadougou (HOSCO), Burkina Faso.
  • Charles Sombié Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
  • Serge Theophile Soubeiga Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou; Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
  • Issoufou Tao Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou, Burkina Faso.
  • Adama Gansane Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
  • Massimo Amicosante Department of Biology, Tor Vergata University of Rome, Italy.
  • Florencia Djigma Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou; Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
  • Dorcas Obiri-Yeboah Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Ghana.
  • Virginio Pietra Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
  • Jacques Simpore | jacques.simpore@yahoo.fr Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Ouaga, Ouagadougou, Burkina Faso; Department of Biology, Tor Vergata University of Rome, Italy.
  • Vittorio Colizzi Department of Biology, Tor Vergata University of Rome, Italy.

Abstract

The low rate of screening for hepatitis B virus (HBV) in pregnant women is a highrisk factor for its vertical transmission. The objectives of this study were: i) to screen pregnant women for HBV infection; ii) vaccinate all children from birth against HBV regardless their mother HBV status; and iii) evaluate after 7 months of birth the level of their AbHBs among babies who received HBV vaccine at birth. Serological markers of HBV (HBsAg, HBeAg, AbHBs, AbHBe, and AbHBc) were determined on venous blood samples from 237 pregnant women and their children using the Abon Biopharm Kit. One hundred and two (102) children received the three doses of the EUVAX B® vaccine respectively at birth, two months and four months of life. Seven months after delivery, venous blood samples were collected from mothers and their children. Antibodies against hepatitis B surface antigen (AbHBs) were measured in vaccinated children using the ELISA Kit AbHBs Quantitative EIA. DNA extraction was performed on samples from HBV-seropositive mothers and their children using the Ribo Virus (HBV Real-TM Qual) Kit and for Real Time PCR, the HBV Real-TM Qual Kit was used. Serological diagnosis in pregnant women revealed 22 (9.28%) hepatitis B surface antigen (HBsAg) positive samples of which 21 were positive for viral DNA by real-time PCR. Among the 22 HBsAg+ women, five (05) transmitted the virus to their children with a vertical transmission rate of 22.73%. A transmission rate of 23.81% (5/21) was found with the PCR method. Analysis of AbHBs levels revealed that 98.31% of the children had an average concentration of 218.07 ± 74.66 IU/L, which is well above the minimum threshold for protection (11 IU/L). This study has confirmed that vertical transmission of HBV is a reality in Burkina Faso and that vaccination at birth would significantly reduce this transmission.

Downloads

Download data is not yet available.
Published
2018-12-21
Section
Original Articles
Keywords:
Viral Hepatitis B, HBsAg, Real- Time PCR, Vertical Transmission, Vaccination.
Statistics
Abstract views: 735

PDF: 540
HTML: 11
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Yelemkoure, E., Yonli, A., Montesano, C., Ouattara, A., Diarra, B., Zohoncon, T., Nadembega, C., Ouedraogo, P., Sombié, C., Soubeiga, S., Tao, I., Gansane, A., Amicosante, M., Djigma, F., Obiri-Yeboah, D., Pietra, V., Simpore, J., & Colizzi, V. (2018). Prevention of mother-to-child transmission of hepatitis B virus in Burkina Faso: Screening, vaccination and evaluation of post-vaccination antibodies against hepatitis B surface antigen in newborns. Journal of Public Health in Africa, 9(3). https://doi.org/10.4081/jphia.2018.816

Most read articles by the same author(s)